Related Experiment Video
Updated: Aug 13, 2026

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice
Published on: December 21, 2019
Pleuropulmonary lesions, ergotamines and asbestos exposure
Gunnar Hillerdal1, Anna Rask-Andersen
1Department of Pulmonary Medicine, Karolinska University Hospital, Stockholm, Sweden. gunnar.hillerdal@karolinska.se
Objectives:
This study investigated the possibility of pleuropulmonary lesions, which can occur as rare but serious side effects of different ergot drugs, occurring more commonly in persons earlier exposed to asbestos.
Methods:
All reports of pleuropulmonary side effects of the ergot drugs used in Sweden in the Swedish side effect registry from 1985 to 2003 were studied. In addition, the literature was reviewed.
Results:
In the registry, 47 men and 3 women were found. Of the men, 24 were exposed to asbestos, and 2 denied such exposure; 2 of the 3 women were exposed. In the literature, 111 patients were found--32 had confirmed exposure and 15 denied it. For most of the patients, it was not possible to determine exposure.
Conclusions:
Enough evidence exists to postulate that earlier asbestos exposure in combination with the intake of ergot drugs can cause pleuropulmonary lesions.
Related Concept Videos
Other Pulmonary Disorders
Chronic Obstructive Pulmonary Disease I: Introduction
Chronic Obstructive Pulmonary Disease II: Emphysema
Pleural Disorders: Types and Brief Description
Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
